<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24583556</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line.</ArticleTitle><Pagination><StartPage>1266</StartPage><EndPage>1273</EndPage><MedlinePgn>1266-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4161/hv.28083</ELocationID><Abstract><AbstractText>The coxsackie A16 virus (CA16), along with enterovirus 71 (EV71), is a primary pathogen that causes hand, foot, and mouth disease (HFMD). To control HFMD, CA16, and EV71 vaccines are needed. In this study, an experimental inactivated CA16 vaccine was prepared using human diploid cells, and the vaccine's immunogenicity was analyzed in mice and rhesus monkeys. The results showed that the neutralizing antibody was developed in a dose-dependent manner, and was sustained for 70 days with an average GMT (geometric mean titer) level of 80 to 90 in immunized mouse and for 56 days with GMT of higher than 300 in monkeys. The neutralizing antibody had a cross-neutralizing activity against different viral strains (genotype A and B), and the specific IFN-&#x3b3;-secreting cell response was activated by these virus strains in an ELISPOT assay. This study provides evidence for the potential use of inactivated CA16 as a candidate for use in vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Erxia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Diseases; Institute of Medical Biology; Chinese Academy of Medicine Sciences &amp; Peking Union Medical College; Kunming, PR China; Jiangsu Convac Biotechnology Co., Ltd; Taizhou Jiangsu, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Diseases; Institute of Medical Biology; Chinese Academy of Medicine Sciences &amp; Peking Union Medical College; Kunming, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Diseases; Institute of Medical Biology; Chinese Academy of Medicine Sciences &amp; Peking Union Medical College; Kunming, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Diseases; Institute of Medical Biology; Chinese Academy of Medicine Sciences &amp; Peking Union Medical College; Kunming, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Che</LastName><ForeName>Yanchun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Diseases; Institute of Medical Biology; Chinese Academy of Medicine Sciences &amp; Peking Union Medical College; Kunming, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pu</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Diseases; Institute of Medical Biology; Chinese Academy of Medicine Sciences &amp; Peking Union Medical College; Kunming, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Chenghong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Diseases; Institute of Medical Biology; Chinese Academy of Medicine Sciences &amp; Peking Union Medical College; Kunming, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Longding</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Diseases; Institute of Medical Biology; Chinese Academy of Medicine Sciences &amp; Peking Union Medical College; Kunming, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Zhanlong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Diseases; Institute of Medical Biology; Chinese Academy of Medicine Sciences &amp; Peking Union Medical College; Kunming, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Shuaiyao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Diseases; Institute of Medical Biology; Chinese Academy of Medicine Sciences &amp; Peking Union Medical College; Kunming, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Diseases; Institute of Medical Biology; Chinese Academy of Medicine Sciences &amp; Peking Union Medical College; Kunming, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Jiangsu Convac Biotechnology Co., Ltd; Taizhou Jiangsu, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Diseases; Institute of Medical Biology; Chinese Academy of Medicine Sciences &amp; Peking Union Medical College; Kunming, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Congwen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Jiangsu Convac Biotechnology Co., Ltd; Taizhou Jiangsu, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qihan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Diseases; Institute of Medical Biology; Chinese Academy of Medicine Sciences &amp; Peking Union Medical College; Kunming, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004171" MajorTopicYN="Y">Diploidy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000882" MajorTopicYN="N">Haplorhini</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055261" MajorTopicYN="N">Immunogenetic Phenomena</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coxsackie virus A 16 type</Keyword><Keyword MajorTopicYN="N">hand, foot, and mouth disease</Keyword><Keyword MajorTopicYN="N">human diploid cell line</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">inactivated vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>2</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24583556</ArticleId><ArticleId IdType="pmc">PMC4896597</ArticleId><ArticleId IdType="doi">10.4161/hv.28083</ArticleId><ArticleId IdType="pii">28083</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang XY, Kang K, Xu YL, Wei HY, Li XL, Ma H, You AG, Chen HM, Xu BL. . [Etiology surveillance of hand-foot-mouth disease in Henan province between 2008 and 2011]. Zhonghua Yu Fang Yi Xue Za Zhi 2012; 46:883 - 7; PMID: 23363860</Citation><ArticleIdList><ArticleId IdType="pubmed">23363860</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc; H-k. . ZHANG Y-j, MIU Z-p, CAI J, QIN S-w, GONG L-m, CHEN Z-p. Epidemiological and pathogenic characteristics of hand,foot,and mouth disease in Zhejiang province, 2008-2009. Chin J Publ Health 2012; 28:105 - 7</Citation></Reference><Reference><Citation>Rabenau HF, Richter M, Doerr HW. . Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol 2010; 199:45 - 51; http://dx.doi.org/10.1007/s00430-009-0133-6; PMID: 19941005</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-009-0133-6</ArticleId><ArticleId IdType="pubmed">19941005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishimaru Y, Nakano S, Yamaoka K, Takami S. . Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch Dis Child 1980; 55:583 - 8; http://dx.doi.org/10.1136/adc.55.8.583; PMID: 6254449</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/adc.55.8.583</ArticleId><ArticleId IdType="pmc">PMC1627055</ArticleId><ArticleId IdType="pubmed">6254449</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia L, Zhao CS, Zhang L, Li S, Zhang DT, Liu BW, Wang QY, Li XY. . [Comparisons of epidemiological and clinical characteristics in children with hand-foot-mouth disease caused by Enterovirus 71 and Coxackievirus A16]. Zhongguo Dang Dai Er Ke Za Zhi 2011; 13:635 - 7; PMID: 21849112</Citation><ArticleIdList><ArticleId IdType="pubmed">21849112</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Liu CF, Yan L, Li JJ, Wang LJ, Qi Y, Cheng RB, Xiong XY. . Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J 2012; 9:8; http://dx.doi.org/10.1186/1743-422X-9-8; PMID: 22230340</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-8</ArticleId><ArticleId IdType="pmc">PMC3268717</ArticleId><ArticleId IdType="pubmed">22230340</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright HT Jr., Landing BH, Lennette EH, McALLISTER RM. . Fatal infection in an infant associated with Coxsackie virus group A, type 16. N Engl J Med 1963; 268:1041 - 4; http://dx.doi.org/10.1056/NEJM196305092681904; PMID: 14001956</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM196305092681904</ArticleId><ArticleId IdType="pubmed">14001956</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi D, Sun L, Chen Q, Zhang N, Han J, Ye X, Su X. . [Comparison of three detection methods for neutralizing antibodies induced by Coxsackievirus A16 vaccine]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2013; 29:287 - 91; PMID: 23643087</Citation><ArticleIdList><ArticleId IdType="pubmed">23643087</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang E, Zhao H, Zhang Y, Liu J, Liao Y, Wang L, Cui P, Yang L, Liu L, Dong C, et al. . . A comparative study of the characteristics of two Coxsackie A virus type 16 strains (genotype B). Sci China Life Sci 2012; 55:336 - 42; http://dx.doi.org/10.1007/s11427-012-4313-z; PMID: 22566090</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-012-4313-z</ArticleId><ArticleId IdType="pubmed">22566090</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Li HY, Han JF, Deng YQ, Li YX, Zhu SY, He YL, Qin ED, Chen R, Qin CF. . Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice. Appl Microbiol Biotechnol 2013; 97:10445 - 52; http://dx.doi.org/10.1007/s00253-013-5257-3; PMID: 24085395</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-013-5257-3</ArticleId><ArticleId IdType="pubmed">24085395</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Yan K, Feng Y, Huang X, Ku Z, Cai Y, Liu F, Shi J, Huang Z. . A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 2012; 30:6642 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.08.071; PMID: 22959985</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.08.071</ArticleId><ArticleId IdType="pubmed">22959985</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Liu Q, Huang X, Li D, Ku Z, Zhang Y, Huang Z. . Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 2013; 31:2215 - 21; http://dx.doi.org/10.1016/j.vaccine.2013.03.007; PMID: 23499596</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.03.007</ArticleId><ArticleId IdType="pubmed">23499596</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Gao R, Shao J, Yao X, Lang S, Wang C, Mao P, Liang Z, Wang J. . A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol 2012; 86:11967 - 76; http://dx.doi.org/10.1128/JVI.00902-12; PMID: 22951825</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00902-12</ArticleId><ArticleId IdType="pmc">PMC3486452</ArticleId><ArticleId IdType="pubmed">22951825</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng-ling L. . LiHua L, Run-xiang Y. Research and preliminary application of Cox A16 antigen detection Kit. Chinese Journal of Health Laboratory Technology 2013; 4:801 - 5</Citation></Reference><Reference><Citation>Raczniak GA, Bulkow LR, Bruce MG, Zanis CL, Baum RL, Snowball MM, Byrd KK, Sharapov UM, Hennessy TW, McMahon BJ. . Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series. J Infect Dis 2013; 207:493 - 6; http://dx.doi.org/10.1093/infdis/jis710; PMID: 23204169</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jis710</ArticleId><ArticleId IdType="pmc">PMC3611760</ArticleId><ArticleId IdType="pubmed">23204169</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Wang J, Liu L, Zhao H, Shi H, Zhang Y, Jiang L, Li Q. . Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys. Hum Vaccin 2010; 6:1028 - 37; http://dx.doi.org/10.4161/hv.6.12.12982; PMID: 21150270</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.6.12.12982</ArticleId><ArticleId IdType="pubmed">21150270</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Gao R, Shao J, Yao X, Lang S, Wang C, Mao P, Liang Z, Wang J. . A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol 2012; 86:11967 - 76; http://dx.doi.org/10.1128/JVI.00902-12; PMID: 22951825</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00902-12</ArticleId><ArticleId IdType="pmc">PMC3486452</ArticleId><ArticleId IdType="pubmed">22951825</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JJ, Su IJ. . Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 2000; 7:523 - 8; http://dx.doi.org/10.1007/BF02253368; PMID: 11060501</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02253368</ArticleId><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Zhang Y, Wang J, Zhao H, Jiang L, Che Y, Shi H, Li R, Mo Z, Huang T, et al. . . Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One 2013; 8:e54451; http://dx.doi.org/10.1371/journal.pone.0054451; PMID: 23372725</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0054451</ArticleId><ArticleId IdType="pmc">PMC3553120</ArticleId><ArticleId IdType="pubmed">23372725</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng Z, Tan XJ, Shao JJ, Zhang Y, Kuang XZ, Zhang X, Xu WB. . [Epidemiology and etiology of hand-foot-and-mouth disease in Shanghai, 2009]. Bing Du Xue Bao 2010; 26:437 - 42; PMID: 21344746</Citation><ArticleIdList><ArticleId IdType="pubmed">21344746</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatproedprai S, Theanboonlers A, Korkong S, Thongmee C, Wananukul S, Poovorawan Y. . Clinical and molecular characterization of hand-foot-and-mouth disease in Thailand, 2008-2009. Jpn J Infect Dis 2010; 63:229 - 33; PMID: 20657060</Citation><ArticleIdList><ArticleId IdType="pubmed">20657060</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Yao X, Bian L, Wu X, Xu M, Liang Z. . Coxsackievirus A16: Epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother 2013; 10; Forthcoming PMID: 24231751</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185891</ArticleId><ArticleId IdType="pubmed">24231751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni H, Yi B, Yin J, Fang T, He T, Du Y, Wang J, Zhang H, Xie L, Ding Y, et al. . . Epidemiological and etiological characteristics of hand, foot, and mouth disease in Ningbo, China, 2008-2011. J Clin Virol 2012; 54:342 - 8; http://dx.doi.org/10.1016/j.jcv.2012.04.021; PMID: 22652041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2012.04.021</ArticleId><ArticleId IdType="pubmed">22652041</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo R, Cao YY, Dai ZZ, Qu SR, Zhuang JY. . [Characteristics of a human diploid cell line, KMB-17]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1981; 3:226 - 30; PMID: 6459859</Citation><ArticleIdList><ArticleId IdType="pubmed">6459859</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega A, Amor&#xf3;s D, Garc&#xed;a de la Torre J. . Global fit and structure optimization of flexible and rigid macromolecules and nanoparticles from analytical ultracentrifugation and other dilute solution properties. Methods 2011; 54:115 - 23; http://dx.doi.org/10.1016/j.ymeth.2010.12.004; PMID: 21163355</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2010.12.004</ArticleId><ArticleId IdType="pubmed">21163355</ArticleId></ArticleIdList></Reference><Reference><Citation>Koticha DK, Barbagallo CA, Rapiejko PJ. Rapid, Ultrafiltration-based Method for Purification of Monoclonal Antibodies from Hybridoma Supernatants. 2008 [2013-10-10].</Citation></Reference><Reference><Citation>Hochstrasser DF, Patchornik A, Merril CR. . Development of polyacrylamide gels that improve the separation of proteins and their detection by silver staining. Anal Biochem 1988; 173:412 - 23; http://dx.doi.org/10.1016/0003-2697(88)90208-4; PMID: 3189819</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-2697(88)90208-4</ArticleId><ArticleId IdType="pubmed">3189819</ArticleId></ArticleIdList></Reference><Reference><Citation>Bey E, Golombick T. . A comparison of three methods for titration of poliovirus vaccines. J Virol Methods 1984; 9:123 - 30; http://dx.doi.org/10.1016/0166-0934(84)90004-1; PMID: 6096387</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-0934(84)90004-1</ArticleId><ArticleId IdType="pubmed">6096387</ArticleId></ArticleIdList></Reference><Reference><Citation>Streeck H, Frahm N, Walker BD. . The role of IFN-gamma Elispot assay in HIV vaccine research. Nat Protoc 2009; 4:461 - 9; http://dx.doi.org/10.1038/nprot.2009.7; PMID: 19282851</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2009.7</ArticleId><ArticleId IdType="pubmed">19282851</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>